growth

(redirected from Growth failure)
Also found in: Dictionary, Medical, Legal, Financial, Encyclopedia, Wikipedia.
Related to Growth failure: failure to thrive
  • noun

Synonyms for growth

Synonyms for growth

Synonyms for growth

(biology) the process of an individual organism growing organically

a progression from simpler to more complex forms

vegetation that has grown

the gradual beginning or coming forth

Related Words

(pathology) an abnormal proliferation of tissue (as in a tumor)

something grown or growing

References in periodicals archive ?
Generally, measurements including weight, height, BMI, IGF-1 and IGFBP-3 are used in evaluation of growth failure caused by adenotonsillar hypertrophy alone where other factors which may affect growth have been excluded (24,31).
Norditropin (somatropin [rDNA origin] injection) is used to treat: children who have growth failure because of low or no growth hormone; children who are short (in stature) and who have Noonan syndrome or Turner syndrome; children who are short (in stature) because they were born small (small for gestational age-SGA) and have not caught-up in growth by age 2 to 4 years; and adults who do not make enough growth hormone.
Norditropin (somatropin [rDNA origin] injection) is used to treat children with growth failure caused by very low or no production of growth hormone.
Norditropin(R) (somatropin [rDNA origin] injection) is used to treat children with growth failure caused by very low or no production of growth hormone.
Unless patients with Prader-Willi Syndrome (PWS) also have a diagnosis of GHD, TEV-TROPIN([R]) is not indicated for treatment of pediatric patients who have growth failure due to genetically confirmed PWS.
IPLEX(TM) was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD).
Norditropin(R) (somatropin [rDNA origin] injection) is indicated for the treatment of children with short stature associated with Turner syndrome, the treatment of children with short stature associated with Noonan syndrome, and treatment of children with growth failure due to inadequate secretion of endogenous growth hormone and for replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:
Norditropin(R) (somatropin [rDNA origin] injection) is indicated for the treatment of children with short stature associated with Noonan syndrome, treatment of children with growth failure due to inadequate secretion of endogenous growth hormone and for replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:
Genotropin is FDA-approved for the treatment of children with hormone-related growth failure, pediatric patients with Prader-Willi Syndrome, and adults with growth hormone deficiency.
IPLEX(TM) was approved by the FDA in December 2005 for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
April 25 /PRNewswire-FirstCall/ -- Insmed Incorporated was honored by the National Organization for Rare Disorders (NORD) last night at its annual Tribute Banquet for the development of IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection) for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
IPLEX was approved in December 2005 for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone.
s Increlex, long-term treatment for growth failure in children with severe primary IGF-1 deficiency; and Insmed's IPLEX, a treatment for growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion.
The company's leading product, IPLEX(TM), was approved as an orphan drug by the United States Food and Drug Administration in December 2005 for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
An estimated 50,000 people in the United States have growth failure due to growth hormone deficiency.